A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Palazestrant: Complete Estrogen Receptor Antagonist
Palbociclib: Palbociclib is an approved CDK 4/6 Inhibitor drug
Study summary
This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).
Eligibility
Primary outcome measure(s)
- Incidence of Dose Limiting Toxicities — From Cycle 1 Day 1 through C1 Day 28
- Characterization and Incidence in Adverse Events and Serious Adverse Events — From initial inform consent date through 30 days post last dose
- Plasma levels of OP-1250 and Palbociclib — Up to 9 months
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Trial Site | Waratah | New South Wales | |
| Clinical Trial Site | Westmead | New South Wales | |
| Clinical Trial Site | South Brisbane | Queensland | |
| Clinical Trial Site | Southport | Queensland | |
| Clinical Trial Site | Clayton | Victoria | |
| Clinical Trial Site | Frankston | Victoria | |
| Clinical Trial Site | Geelong | Victoria | |
| Clinical Trial Site | Nedlands | Western Australia |
On this site
📄 Ibrance (palbociclib) drug profile →Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05266105 on ClinicalTrials.gov ↗ ← All trials in Australia